8 recruiting, 3 active not recruiting, 2 completed, 2 not yet recruiting. 18 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 18 | Recruiting 8, Active not recruiting 3, Completed 2, Not yet recruiting 2, Terminated 2, Unknown 1 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Advanced Solid Cancer: new trials by email Literature Review of Advanced Solid Cancer trials Research Report on Advanced Solid Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1 Study of NW-301V TCR-T Cells in Advanced Solid Tumors With KRAS G12V Mutation Fludarabine, Cyclophosphamide, NW-301V - Advanced Solid Cancer, Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 | Not yet recruiting | Neowise Biotechnology | 66 | 2026-10-01 | 2026-10-15 |
| SIM0613 in Participants With Advanced Solid Tumors SIM0613 - Advanced Solid Cancer | Phase 1 | Recruiting | Jiangsu Simcere Pharmaceutical Co., Ltd. | 294 | 2026-05-15 | 2026-06-01 |
| A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab BI 3819026, Ezabenlimab (BI 754091) - Advanced Solid Cancer, Metastatic Solid Cancer | Phase 1 | Recruiting | Boehringer Ingelheim | 60 | 2026-05-01 | 2026-09-29 |
| A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors SIM0609 for injection, dose expansion of SIM0609 in CRC, dose expansion of SIM0609 in GC/GEJC cohort - Advanced Solid Cancer | Phase 1 | Recruiting | Jiangsu Simcere Pharmaceutical Co., Ltd. | 232 | 2025-11-07 | 2025-12-05 |
| A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors APX-343A, Pembrolizumab - Advanced Solid Cancer, Advanced Solid Tumor (Phase 1) | Phase 1 | Recruiting | Aptabio Therapeutics, Inc. | 110 | 2025-10-24 | 2026-10-09 |
| Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors KXV01 TCR Lentinvivo Injection - Advanced Solid Cancer | Phase 1 | Recruiting | TCRx Therapeutics Co.Ltd | 30 | 2025-10-01 | 2026-10-26 |
| Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors SYN608 - Advanced Solid Cancer, Metastatic Solid Tumor | Phase 1 | Not yet recruiting | Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd | 105 | 2025-07-31 | 2025-07-28 |
| A Study of MHB046C Injection in Patients With Advanced Solid Tumors MHB046C - Advanced Solid Cancer | Phase 1 / Phase 2 | Recruiting | Minghui Pharmaceutical (Hangzhou) Ltd | 200 | 2025-07-17 | 2026-10-09 |
| A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation ARV-806 - KRAS G12D Mutation, Advanced Solid Cancer | Phase 1 / Phase 2 | Active not recruiting | Arvinas Inc. | 76 | 2025-05-29 | 2026-09-16 |
| Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors SYN818 - Advanced Solid Cancer, Metastatic Solid Tumor | Phase 1 | Recruiting | Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd | 30 | 2024-11-21 | 2025-07-20 |
| ORB-011 In Patients With Advanced Solid Tumors ORB-011 - Advanced Solid Cancer | Phase 1 | Completed | Orionis Biosciences Inc | 55 | 2023-08-21 | 2026-06-12 |
| A Phase I Study Of JS015 in Patients With Advanced Solid Tumors JS015 - Advanced Solid Cancer | Phase 1 | Completed | Shanghai Junshi Bioscience Co., Ltd. | 12 | 2023-02-13 | 2026-07-20 |
| A Study of SHR-A1904 in Patients With Advanced Solid Cancer SHR-A1904 - Advanced Solid Cancer | Phase 1 | Active not recruiting | Shanghai Hengrui Pharmaceutical Co., Ltd. | 107 | 2021-07-01 | 2025-03-25 |
| A Phase I Study of BPI-16350 in Patients with Advanced Solid Tumor BPI-16350 - Advanced Solid Cancer | Phase 1 | Active not recruiting | Betta Pharmaceuticals Co., Ltd. | 54 | 2019-07-18 | 2025-01-27 |
| APG-2449 in Patients With Advanced Solid Tumors APG-2449 - Advanced Solid Cancer, Non Small Cell Lung Cancer | Phase 1 | Recruiting | Ascentage Pharma Group Inc. | 165 | 2019-05-27 | 2026-07-23 |
| Clinical Trial of BAT8003 (for Injection) for Patients With Advanced Epithelial Cancer BAT8003 - Advanced Solid Cancer | Phase 1 | Terminated | Bio-Thera Solutions | 5 | 2019-03-15 | 2023-05-01 |
| Safety and Tolerability of SH-1028 in Patients With Advanced Solid Cancer SH-1028 - Advanced Solid Cancer | Phase 1 | Unknown | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 14 | 2018-09-13 | 2019-01-29 |
| A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies henatinib - Advanced Solid Cancer | Phase 1 | Terminated | Jiangsu HengRui Medicine Co., Ltd. | 44 | 2010-09-01 | 2012-12-21 |
Ovarian Neoplasms (4) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Neoplasm Metastasis (2) · Pancreatic Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Adenocarcinoma of Lung (1) · Cholangiocarcinoma (1) · Colonic Neoplasms (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Gallbladder Neoplasms (1) · Melanoma (1) · Mesothelioma, Malignant (1)
Endocrine Gland Neoplasms (5) · Endocrine System Diseases (5) · Neoplasms (5) · Neoplasms by Site (5) · Adnexal Diseases (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Genital Diseases (4) · Genital Diseases, Female (4) · Genital Neoplasms, Female (4) · Gonadal Disorders (4) · Ovarian Diseases (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Digestive System Diseases (3)
2-((5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-5-(2-hydroxy-3-morpholinopropyl)-3-methyl-5,6,7,8-tetrahydro-1H-pyrrolo(3,2-c)azepin-4-ketone (1) · Cyclophosphamide (1) · Injections (1) · SH-1028 (1) · fludarabine (1) · pembrolizumab (1)
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd (2) · Jiangsu Simcere Pharmaceutical Co., Ltd. (2) · Aptabio Therapeutics, Inc. (1) · Arvinas Inc. (1) · Ascentage Pharma Group Inc. (1) · Betta Pharmaceuticals Co., Ltd. (1) · Bio-Thera Solutions (1) · Boehringer Ingelheim (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Minghui Pharmaceutical (Hangzhou) Ltd (1) · Nanjing Sanhome Pharmaceutical, Co., Ltd. (1) · Neowise Biotechnology (1) · Orionis Biosciences Inc (1) · Shanghai Hengrui Pharmaceutical Co., Ltd. (1) · Shanghai Junshi Bioscience Co., Ltd. (1)
China (14) · United States (3) · Japan (1) · South Korea (1) · Spain (1)
Jin Li, Medical Doctor (1) · Jinming Yu, Medical Doctor (1) · Li Zhang, Professor (1) · Robert Petit, PhD (1)
PMID 35820889, PMID 40670772, PMID 41146927
2025 (2)